Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MLYS NYSE:PHR NASDAQ:QDEL NASDAQ:SNDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMLYSMineralys Therapeutics$34.80+5.1%$15.59$8.24▼$35.09$2.20B-0.292.23 million shs3.74 million shsPHRPhreesia$28.09-10.0%$28.34$17.07▼$32.76$1.86B0.72819,069 shs2.67 million shsQDELQuidelOrtho$28.68+3.2%$27.06$22.05▼$49.45$1.89B0.141.11 million shs971,432 shsSNDAShanda Interactive Entertainment$25.73+12.8%$0.00$19.34▼$32.90$479.80M1.8352,862 shs32,857 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMLYSMineralys Therapeutics+5.07%+124.81%+158.54%+115.88%+194.42%PHRPhreesia-10.27%-11.29%+3.61%+4.91%+16.22%QDELQuidelOrtho+3.20%-0.03%+22.35%-2.88%-28.94%SNDAShanda Interactive Entertainment-0.42%-0.45%+4.37%+1.17%-8.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMLYSMineralys Therapeutics$34.80+5.1%$15.59$8.24▼$35.09$2.20B-0.292.23 million shs3.74 million shsPHRPhreesia$28.09-10.0%$28.34$17.07▼$32.76$1.86B0.72819,069 shs2.67 million shsQDELQuidelOrtho$28.68+3.2%$27.06$22.05▼$49.45$1.89B0.141.11 million shs971,432 shsSNDAShanda Interactive Entertainment$25.73+12.8%$0.00$19.34▼$32.90$479.80M1.8352,862 shs32,857 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMLYSMineralys Therapeutics+5.07%+124.81%+158.54%+115.88%+194.42%PHRPhreesia-10.27%-11.29%+3.61%+4.91%+16.22%QDELQuidelOrtho+3.20%-0.03%+22.35%-2.88%-28.94%SNDAShanda Interactive Entertainment-0.42%-0.45%+4.37%+1.17%-8.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMLYSMineralys Therapeutics 2.80Moderate Buy$36.605.17% UpsidePHRPhreesia 3.00Buy$33.3118.57% UpsideQDELQuidelOrtho 2.33Hold$39.2036.68% UpsideSNDAShanda Interactive Entertainment 2.00Hold$26.001.07% UpsideCurrent Analyst Ratings BreakdownLatest SNDA, QDEL, MLYS, and PHR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025PHRPhreesiaCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$34.00 ➝ $38.009/5/2025PHRPhreesiaNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$29.00 ➝ $35.009/5/2025PHRPhreesiaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$33.00 ➝ $34.009/5/2025PHRPhreesiaDA DavidsonSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$33.009/3/2025MLYSMineralys TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$15.00 ➝ $26.009/3/2025PHRPhreesiaStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$32.008/28/2025MLYSMineralys TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$38.00 ➝ $43.008/27/2025PHRPhreesiaMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$36.008/13/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.008/7/2025QDELQuidelOrthoUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$29.00 ➝ $26.008/6/2025QDELQuidelOrthoCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $40.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/APHRPhreesia$419.81M3.98N/AN/A$4.56 per share6.16QDELQuidelOrtho$2.78B0.70$36.77 per share0.78$44.38 per share0.65SNDAShanda Interactive Entertainment$255.32M1.92N/AN/A($14.07) per share-1.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMLYSMineralys Therapeutics-$177.81M-$3.56N/AN/AN/AN/A-70.44%-65.51%11/10/2025 (Estimated)PHRPhreesia-$58.53M-$0.74N/AN/AN/A-5.35%-9.00%-6.20%N/AQDELQuidelOrtho-$2.05B-$6.54N/A8.93N/A-16.10%5.29%2.43%11/6/2025 (Estimated)SNDAShanda Interactive Entertainment-$21.11M-$1.85N/AN/AN/A-4.02%N/A-6.11%N/ALatest SNDA, QDEL, MLYS, and PHR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/4/2025Q2 2026PHRPhreesia-$0.07$0.01+$0.08$0.01$116.39 million$117.26 million8/12/2025Q2 2025MLYSMineralys Therapeutics-$0.78-$0.66+$0.12-$0.66N/AN/A8/5/2025Q2 2025QDELQuidelOrtho$0.0122$0.12+$0.1078-$3.77$612.36 million$613.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMLYSMineralys TherapeuticsN/AN/AN/AN/AN/APHRPhreesiaN/AN/AN/AN/AN/AQDELQuidelOrthoN/AN/AN/AN/AN/ASNDAShanda Interactive EntertainmentN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMLYSMineralys TherapeuticsN/A15.1215.12PHRPhreesia0.021.951.95QDELQuidelOrtho0.741.120.62SNDAShanda Interactive Entertainment6.972.342.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMLYSMineralys Therapeutics84.46%PHRPhreesia92.10%QDELQuidelOrtho99.00%SNDAShanda Interactive Entertainment87.55%Insider OwnershipCompanyInsider OwnershipMLYSMineralys Therapeutics25.56%PHRPhreesia5.50%QDELQuidelOrtho0.79%SNDAShanda Interactive Entertainment5.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMLYSMineralys Therapeutics2866.29 million49.35 millionOptionablePHRPhreesia2,08259.50 million56.23 millionOptionableQDELQuidelOrtho6,60067.90 million67.36 millionOptionableSNDAShanda Interactive Entertainment3,95519.07 million18.12 millionNot OptionableSNDA, QDEL, MLYS, and PHR HeadlinesRecent News About These CompaniesSonida Senior Living (SNDA) Reports Q2 Loss, Beats Revenue EstimatesAugust 11, 2025 | zacks.comSonida Senior Living, Inc. (SNDA) Q2 2025 Earnings Conference Call TranscriptAugust 11, 2025 | seekingalpha.comSonida Senior Living Celebrates Growth and Community in Greater Atlanta RegionJuly 30, 2025 | businesswire.comVista Building at The Wellington at North Bend Crossing Secures Ohio Licensure, Opening Doors for New Assisted Living and Memory Care ResidentsJuly 30, 2025 | businesswire.comSonida Senior Living, Inc. (SNDA) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comSonida Senior Living (SNDA) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2025 | zacks.comSonida Senior Living Announces First Quarter 2025 ResultsMay 12, 2025 | businesswire.comSonida Announces Participation in Upcoming ConferencesMay 8, 2025 | businesswire.comThe Wellington at North Bend Crossing Expands Assisted Living and Memory Care Services, Coming Summer 2025May 2, 2025 | businesswire.comSonida Senior Living, Inc. (SNDA) Q4 2024 Earnings Call TranscriptMarch 17, 2025 | seekingalpha.comSonida Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Conference CallMarch 3, 2025 | businesswire.comSonida to Participate in Citi's 30th Annual Global Property CEO ConferenceFebruary 17, 2025 | businesswire.comSonida Senior Living Advances Clinical Excellence with August HealthFebruary 6, 2025 | businesswire.comSonida Announces Latest Asset Acquisition and Closing of Fannie Mae Maturity ModificationsJanuary 6, 2025 | businesswire.comSonida Senior Living, Inc. (SNDA) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | seekingalpha.comSonida Senior Living Announces Third Quarter 2024 ResultsNovember 13, 2024 | businesswire.comSonida Continues Executing on its Accretive Growth and Capital Allocation Strategy with $48 Million of InvestmentsNovember 5, 2024 | businesswire.comSunda Energy Share Chat (SNDA)November 4, 2024 | lse.co.ukInteractive Harry Potter art experience to open on Sentosa on Nov 22November 1, 2024 | straitstimes.comSSonida Announces Third Quarter 2024 Earnings Release Date and Conference CallOctober 29, 2024 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNDA, QDEL, MLYS, and PHR Company DescriptionsMineralys Therapeutics NASDAQ:MLYS$34.80 +1.68 (+5.07%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$34.62 -0.17 (-0.50%) As of 09/5/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Phreesia NYSE:PHR$28.09 -3.12 (-10.00%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$29.07 +0.98 (+3.49%) As of 09/5/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware.QuidelOrtho NASDAQ:QDEL$28.68 +0.89 (+3.20%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$28.68 0.00 (0.00%) As of 09/5/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.Shanda Interactive Entertainment NASDAQ:SNDAShanda Interactive Entertainment Limited (Shanda Interactive) is an interactive entertainment media company. The Company offers a range of entertainment content portfolio, including among other things, massively multiplayer online role-playing game (MMORPG), advanced casual games and browser-based games without user-end software through Shanda Games, online (Internet and wireless value added services (WVAS)) and offline literature publication through Cloudary Corporation, a social network game community, including among others, online chess and board games, e-sports game platform and table game platform through Shanda Casual Community, WVAS and music through Hurray and online video through Ku6. In February 2012, Shanda Interactive merged with Premium Lead Company Limited and New Era Investment Holding Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
